AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29295829 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication therapy management intervention
Number of subjects: 141
Study 27720040 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA supplementation (high dose)
Number of subjects: 17
Study 27720040 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA supplementation (low dose)
Number of subjects: 17
Study 27720040 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 23660572 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel training program (NT)
Number of subjects: 133
Study 23660572 — intervention group
Group type: COMPARATOR
Intervention: Traditional Army physical training (TT)
Number of subjects: 133
Study 23792178 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Therapy (CT)
Number of subjects: 0
Study 20739842 — intervention group
Group type: EXPERIMENTAL
Intervention: SLND alone
Number of subjects: 891
Study 20739842 — intervention group
Group type: COMPARATOR
Intervention: SLND + ALND
Number of subjects: 891
Study 18467618 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovenous laser ablation (ELA) of refluxing superficial axial veins using the CoolTouch CTEV 1320 nm laser and ultrasound-guided sclerotherapy of associated varicose veins with foamed sodium tetradecyl sulphate (STS).
Number of subjects: 35
Study 18467618 — intervention group
Group type: COMPARATOR
Intervention: Non-operative cohort (control group).
Number of subjects: 35
Study 15939027 — intervention group
Group type: EXPERIMENTAL
Intervention: Information entropy analysis with no assumption on data distribution
Number of subjects: 0
Study 15939027 — intervention group
Group type: EXPERIMENTAL
Intervention: Information entropy analysis assuming normal distribution
Number of subjects: 0
Study 15939027 — intervention group
Group type: EXPERIMENTAL
Intervention: Mutual information analysis
Number of subjects: 0
Study 12826992 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine (15 mg/day)
Number of subjects: 26
Study 12826992 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 10403850 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine (2.0 mg intravenously)
Number of subjects: 21
Study 10403850 — intervention group
Group type: COMPARATOR
Intervention: Placebo (intravenous saline)
Number of subjects: 21
Study 8899087 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbonate 1000 mg plus vitamin D 250 IU (Oscal)
Number of subjects: 0
Study 8899087 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1647337 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine, 30 mg three times daily for 10 days
Number of subjects: 35
Study 1647337 — intervention group
Group type: COMPARATOR
Intervention: Placebo, similar dosage and duration as treatment group
Number of subjects: 35
Study 6344956 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal gastric vagotomy (PGV)
Number of subjects: 153
Study 6344956 — intervention group
Group type: COMPARATOR
Intervention: Truncal vagotomy and pyloroplasty (TVP)
Number of subjects: 153
Study 31335802 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tenofovir‐based pre‐exposure prophylaxis (PrEP)
Number of subjects: 0
Study 30037068 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric Restriction (CR) 1000 cal/day
Number of subjects: 48
Study 30037068 — intervention group
Group type: COMPARATOR
Intervention: Resveratrol (RSV) 500 mg/day
Number of subjects: 48
Study 27372432 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective COX-2 inhibitor etoricoxib
Number of subjects: 16
Study 27372432 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 16
Study 23356505 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc sulphate/folic acid
Number of subjects: 0
Study 23356505 — intervention group
Group type: COMPARATOR
Intervention: Folic acid
Number of subjects: 0
Study 23356505 — intervention group
Group type: COMPARATOR
Intervention: Zinc sulphate
Number of subjects: 0
Study 23356505 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23390784 — intervention group
Group type: EXPERIMENTAL
Intervention: Periarticular injection of 20 ml 0.25% bupivacaine
Number of subjects: 99
Study 23390784 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline solution (control)
Number of subjects: 99
Study 20937112 — intervention group
Group type: EXPERIMENTAL
Intervention: PRIMUS Activities
Number of subjects: 911
Study 20937112 — intervention group
Group type: EXPERIMENTAL
Intervention: PRIMUS QoL
Number of subjects: 911
Study 20937112 — intervention group
Group type: EXPERIMENTAL
Intervention: U-FIS
Number of subjects: 911
Study 18657677 — intervention group
Group type: EXPERIMENTAL
Intervention: ADD1 variant carriers (black patients)
Number of subjects: 5979
Study 18657677 — intervention group
Group type: EXPERIMENTAL
Intervention: ADD1 variant carriers (Hispanic patients)
Number of subjects: 5979
Study 18657677 — intervention group
Group type: EXPERIMENTAL
Intervention: ADD1 variant carriers (white patients)
Number of subjects: 5979
Study 18657677 — intervention group
Group type: EXPERIMENTAL
Intervention: All-cause death (secondary outcome)
Number of subjects: 5979
Study 18657677 — intervention group
Group type: COMPARATOR
Intervention: Diuretic use
Number of subjects: 5979
Study 15915026 — intervention group
Group type: EXPERIMENTAL
Intervention: Active nicotine-containing patches
Number of subjects: 121
Study 15915026 — intervention group
Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 121
Study 12679359 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal exercise (graded upright cycle ergometry to volitional exhaustion)
Number of subjects: 8
Study 12679359 — intervention group
Group type: COMPARATOR
Intervention: No exercise
Number of subjects: 8
Study 12679359 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal exercise
Number of subjects: 8
Study 10954343 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin 600 mg
Number of subjects: 10
Study 10954343 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 800 mg
Number of subjects: 10
Study 10954343 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 9252901 — intervention group
Group type: EXPERIMENTAL
Intervention: 13C-xylose (50 mg)
Number of subjects: 35
Study 9252901 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment
Number of subjects: 35
Study 9252901 — intervention group
Group type: COMPARATOR
Intervention: Control groups (10 mg and 25 mg 13C-xylose)
Number of subjects: 35
Study 8391042 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphoblastoid interferon (administered in a step-down schedule for 12 months)
Number of subjects: 72
Study 8391042 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 72
Study 8391042 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphoblastoid interferon
Number of subjects: 72
Study 3505532 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (80 mg oral administration)
Number of subjects: 30
Study 3505532 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 29335043 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic repair using a mirrored L‐shaped flap without stenting (Group A)
Number of subjects: 72
Study 29335043 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic repair using stenting without a flap (Group B)
Number of subjects: 72
Study 28410809 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy 60Gy/30 fractions with oral vinorelbine 50mg 3 times weekly
Number of subjects: 117
Study 28410809 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy 66Gy/33 fractions with oral vinorelbine 50mg 3 times weekly
Number of subjects: 117
Study 26154736 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior subtenon's injection of 40 mg of triamcinolone acetonide
Number of subjects: 42
Study 26154736 — intervention group
Group type: COMPARATOR
Intervention: Grid laser photocoagulation (GLP) combined with posterior subtenon's triamcinolone injection
Number of subjects: 42
Study 23496861 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine e-cigarettes (16 mg)
Number of subjects: 657
Study 23496861 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch (21 mg)
Number of subjects: 657
Study 23496861 — intervention group
Group type: COMPARATOR
Intervention: Placebo e-cigarettes (no nicotine)
Number of subjects: 657
Study 21680726 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glycemic control therapy (IT) for 2 weeks
Number of subjects: 48
Study 17519926 — intervention group
Group type: EXPERIMENTAL
Intervention: Intake of vitamin C-rich vegetables (bell peppers and broccoli)
Number of subjects: 1985
Study 17519926 — intervention group
Group type: COMPARATOR
Intervention: Fruit and other vegetables
Number of subjects: 1985
Study 17519926 — intervention group
Group type: COMPARATOR
Intervention: Vitamin A intakes
Number of subjects: 1985
Study 16410147 — intervention group
Group type: EXPERIMENTAL
Intervention: PNP care
Number of subjects: 76
Study 16410147 — intervention group
Group type: COMPARATOR
Intervention: RES care
Number of subjects: 76
Study 15012688 — intervention group
Group type: EXPERIMENTAL
Intervention: Low GDP solution (pH 7.0)
Number of subjects: 26
Study 15012688 — intervention group
Group type: COMPARATOR
Intervention: High GDP solution (pH 5.5)
Number of subjects: 26
Study 10897510 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling (70 patients)
Number of subjects: 136
Study 10897510 — intervention group
Group type: COMPARATOR
Intervention: GP care (66 patients)
Number of subjects: 136
Study 9085977 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS-guided group (anesthetic drug doses increased to produce a lower BIS)
Number of subjects: 300
Study 9085977 — intervention group
Group type: COMPARATOR
Intervention: Control group (BIS recorded, no action taken)
Number of subjects: 300
Study 8441793 — intervention group
Group type: EXPERIMENTAL
Intervention: SAMe 1,600 mg/day
Number of subjects: 80
Study 8441793 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 31980861 — intervention group
Group type: EXPERIMENTAL
Intervention: Anatomically contoured fibular plates
Number of subjects: 0
Study 31980861 — intervention group
Group type: COMPARATOR
Intervention: Intramedullary nail fixation
Number of subjects: 0
Study 31080092 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone peer coaching (weekly 30-min calls for 6 months)
Number of subjects: 115
Study 27973335 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive coronary multislice computed tomography angiography (MSCT) assessment
Number of subjects: 0
Study 27973335 — intervention group
Group type: COMPARATOR
Intervention: Invasive conventional angiography assessment
Number of subjects: 0
Study 25958936 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep disturbance measured at 6 weeks using Beck Depression Inventory (v.2) item 16.
Number of subjects: 134
Study 25958936 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep disturbance at 4 months.
Number of subjects: 134
Study 25958936 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety and depression assessed by the Hospital Anxiety and Depression Scale.
Number of subjects: 134
Study 25260214 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 11
Study 25260214 — intervention group
Group type: COMPARATOR
Intervention: Present Centered Therapy (PCT)
Number of subjects: 11
Study 21988096 — intervention group
Group type: EXPERIMENTAL
Intervention: TND + MI
Number of subjects: 1186
Study 21988096 — intervention group
Group type: EXPERIMENTAL
Intervention: TND-Only
Number of subjects: 1186
Study 21988096 — intervention group
Group type: COMPARATOR
Intervention: SCC
Number of subjects: 1186
Study 19874634 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein breakfast with whey
Number of subjects: 35
Study 19874634 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein breakfast with alpha-lac
Number of subjects: 35
Study 19874634 — intervention group
Group type: COMPARATOR
Intervention: Normal-protein breakfast
Number of subjects: 35
Study 16938153 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil-propofol
Number of subjects: 60
Study 16938153 — intervention group
Group type: COMPARATOR
Intervention: Sufentanil-propofol
Number of subjects: 60
Study 16275243 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxiplex/AP Gel
Number of subjects: 28
Study 16275243 — intervention group
Group type: COMPARATOR
Intervention: No further treatment (Control)
Number of subjects: 28
Study 12101459 — intervention group
Group type: EXPERIMENTAL
Intervention: AMO 'ARRAY' multifocal IOLs
Number of subjects: 69
Study 12101459 — intervention group
Group type: EXPERIMENTAL
Intervention: Storz 'TRUEVISTA' bifocal IOLs
Number of subjects: 69
Study 12101459 — intervention group
Group type: COMPARATOR
Intervention: Monofocal IOLs
Number of subjects: 69
Study 9857882 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarpogrelate 200 mg orally administered
Number of subjects: 22
Study 9857882 — intervention group
Group type: COMPARATOR
Intervention: Control (without sarpogrelate)
Number of subjects: 22
Study 7596637 — intervention group
Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine (DEC)
Number of subjects: 80
Study 7596637 — intervention group
Group type: EXPERIMENTAL
Intervention: Mebendazole (MBZ)
Number of subjects: 80
Study 7596637 — intervention group
Group type: COMPARATOR
Intervention: Control (neither DEC nor MBZ)
Number of subjects: 80
Study 2228077 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin suppositories (100 mg 1‐3 times a day)
Number of subjects: 40
Study 2228077 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 26375 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilocarpine 4% solution at pH 4.1
Number of subjects: 24
Study 26375 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilocarpine 4% solution at pH 5.8
Number of subjects: 24
Study 30129937 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline (AMI)
Number of subjects: 50
Study 30129937 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline (NOR)
Number of subjects: 50
Study 30129937 — intervention group
Group type: EXPERIMENTAL
Intervention: Both AMI and NOR
Number of subjects: 50
Study 29880554 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact aspiration
Number of subjects: 231
Study 29880554 — intervention group
Group type: COMPARATOR
Intervention: Stent retriever
Number of subjects: 231
Study 29880554 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact aspiration and Stent retriever
Number of subjects: 231
Study 27802960 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-layered soft silicone foam dressing
Number of subjects: 366
Study 27802960 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 366
Study 24582071 — intervention group
Group type: EXPERIMENTAL
Intervention: INRPlus electronic assistant
Number of subjects: 551
Study 24582071 — intervention group
Group type: COMPARATOR
Intervention: Standard fluindione management (control)
Number of subjects: 551
Study 24582071 — intervention group
Group type: EXPERIMENTAL
Intervention: INRPlus electronic assistant (compliant patients)
Number of subjects: 551
Study 24582071 — intervention group
Group type: EXPERIMENTAL
Intervention: INRPlus electronic assistant (non-compliant patients)
Number of subjects: 551
Study 24582071 — intervention group
Group type: COMPARATOR
Intervention: Control group (reference patients)
Number of subjects: 551
Study 22169588 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention
Number of subjects: 47
Study 22169588 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 47
Study 19156082 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrolysin
Number of subjects: 38
Study 19156082 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 17485058 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum therapy
Number of subjects: 54
Study 17485058 — intervention group
Group type: COMPARATOR
Intervention: Conventional gauze therapy
Number of subjects: 54
Study 15168040 — intervention group
Group type: EXPERIMENTAL
Intervention: High intake diet (810 g/10 MJ of vegetables, berries, and apple)
Number of subjects: 77
Study 15168040 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intake diet (196 g/10 MJ of vegetables, berries, and apple)
Number of subjects: 77
Study 15168040 — intervention group
Group type: COMPARATOR
Intervention: Control group (19 healthy volunteers)
Number of subjects: 77
Study 11248360 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (300 mg twice daily for 3 months)
Number of subjects: 32
Study 11248360 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 32
Study 9676168 — intervention group
Group type: COMPARATOR
Intervention: PTCA alone (n = 208)
Number of subjects: 410
Study 9676168 — intervention group
Group type: EXPERIMENTAL
Intervention: PTCA plus heparin-coated stent (n = 202)
Number of subjects: 410
Study 8088182 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipiodolization with gelatin sponge (Group A, n = 24)
Number of subjects: 52
Study 8088182 — intervention group
Group type: COMPARATOR
Intervention: Lipiodolization alone (Group B, n = 28)
Number of subjects: 52
Study 2573301 — intervention group
Group type: EXPERIMENTAL
Intervention: Topically applied azatadine base
Number of subjects: 0
Study 2573301 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemically administered terfenadine
Number of subjects: 0
Study 2573301 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemically administered cetirizine
Number of subjects: 0
Study 2573301 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 4232743 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 0
Study 4232743 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30528653 — intervention group
Group type: COMPARATOR
Intervention: Prostate-only IMRT (PO) 74 Gy/37 fractions
Number of subjects: 124
Study 30528653 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostate and pelvic lymph node IMRT (P&P) 74 Gy/37 fractions to prostate, 60 Gy/37 fractions to pelvis
Number of subjects: 124
Study 29247107 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose prednisolone (0.5 mg/kg daily) plus rituximab (375 mg/m2 weekly)
Number of subjects: 140
Study 29247107 — intervention group
Group type: COMPARATOR
Intervention: High-dose prednisolone (1 mg/kg daily) plus rituximab
Number of subjects: 140
Study 26011742 — intervention group
Group type: EXPERIMENTAL
Intervention: Crushed ALO-02 (30 mg oxycodone/3.6 mg naltrexone)
Number of subjects: 32
Study 26011742 — intervention group
Group type: COMPARATOR
Intervention: Oxycodone immediate-release (IR) (30 mg)
Number of subjects: 32
Study 26011742 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 24360132 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS and psychotherapy for an average of 21 sessions
Number of subjects: 90
Study 24360132 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 90
Study 22302679 — intervention group
Group type: EXPERIMENTAL
Intervention: ARR plus elevated serum aldosterone concentration (SAC)
Number of subjects: 466
Study 22302679 — intervention group
Group type: EXPERIMENTAL
Intervention: Log‐ARR
Number of subjects: 466
Study 22302679 — intervention group
Group type: COMPARATOR
Intervention: ARR
Number of subjects: 466
Study 22302679 — intervention group
Group type: EXPERIMENTAL
Intervention: ARR plus SAC
Number of subjects: 466
Study 20205018 — intervention group
Group type: EXPERIMENTAL
Intervention: E-mail invitation from a friend
Number of subjects: 432
Study 20205018 — intervention group
Group type: EXPERIMENTAL
Intervention: Weak arguments in e-mail invitations
Number of subjects: 432
Study 20205018 — intervention group
Group type: COMPARATOR
Intervention: E-mail invitation from an institution
Number of subjects: 432
Study 17213965 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate exercise (60% of heart rate reserve)
Number of subjects: 59
Study 17213965 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately-intense exercise (70% of heart rate reserve)
Number of subjects: 59
Study 17213965 — intervention group
Group type: COMPARATOR
Intervention: Movie-watching control group
Number of subjects: 59
Study 17213965 — intervention group
Group type: EXPERIMENTAL
Intervention: All exercise groups combined
Number of subjects: 59
Study 15908836 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 56
Study 15908836 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 12111873 — intervention group
Group type: EXPERIMENTAL
Intervention: Incorporation of baseline covariates in estimating equations
Number of subjects: 0
Study 12111873 — intervention group
Group type: COMPARATOR
Intervention: Control arm only
Number of subjects: 0
Study 10360713 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly measurement of access flow (QAT)
Number of subjects: 103
Study 10360713 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly measurement of static venous pressure (VPS)
Number of subjects: 103
Study 10360713 — intervention group
Group type: COMPARATOR
Intervention: Control (no monthly monitoring)
Number of subjects: 103
Study 7585753 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 25 mg
Number of subjects: 18
Study 7585753 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 2008802 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine A (oral, 3 doses at 14-day intervals)
Number of subjects: 3
Study 2008802 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine B (oral, 3 doses at 14-day intervals)
Number of subjects: 3
Study 2008802 — intervention group
Group type: COMPARATOR
Intervention: Control (100 ml 5% NaHCO3, oral, 3 doses at 14-day intervals)
Number of subjects: 3
Study 7121333 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary Care Curriculum (PCC)
Number of subjects: 0
Study 7121333 — intervention group
Group type: COMPARATOR
Intervention: Conventional Curriculum
Number of subjects: 0
Study 29580634 — intervention group
Group type: EXPERIMENTAL
Intervention: D-Cycloserine (DCS) 100 mg
Number of subjects: 25
Study 29580634 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 28832388 — intervention group
Group type: EXPERIMENTAL
Intervention: Non‐op treatment
Number of subjects: 83
Study 28832388 — intervention group
Group type: COMPARATOR
Intervention: OP treatment with hook plate fixation
Number of subjects: 83